College of Pharmacy

Print Friendly
QingyuZhou

Qingyu Zhou, Assistant Professor, Pharmaceutical Sciences

Assistant Professor, Cop Dept Of Pharmaceutical Science

Cop Dept Of Pharmaceutical Science

Contact Info 12901 Bruce B. Downs Blvd.
MDC 30
Tampa, FL 33612

Academic Email: qzhou1@health.usf.edu

Academic Phone: (813) 974-7081

Education

  • PhD, Pharmaceutical Sciences, National University Of Singapore, 2003
  • Ph.D., Pharmaceutical Sciences, National University of Singapore, 2003

Interdisciplinary and Emerging Signature Programs

  • Cancer Biology
  • Other

Research Interests

  • Dr. Zhou’s major areas of interest and research expertise are in the experimental therapeutics of metastatic tumors and acquired resistance to molecularly targeted cancer therapies.One of Dr. Zhou’s current research programs concerns the development of novel preclinical approaches to guide the use of targeted therapeutic agents for the treatment of brain metastases. The mission begins with the establishment of an in vivo brain metastasis model that possesses the blood-brain barrier (BBB) and is able to replicate the native environment of brain metastases; continues with the characterization of the pharmacokinetic (PK) and pharmacodynamic (PD) properties of a targeted therapeutic agent in the established in vivo model; and is followed by quantitative evaluation of the relationship between drug distribution in the target tissue and tumor response to the treatment through the measurement of PD biomarkers representing the specific signaling transduction networks in tumor cells and their microenvironment – with each step working towards building a framework to guide the rational design of drug dosing regimens that lead to optimal tumor drug concentrations and maximal antineoplastic effects. Dr. Zhou’s research also extends to the mechanistic study of acquired resistance to targeted therapy in lung cancers using in vivo drug resistant tumor models. The goal is to provide a means to understand the sequence of biologically programmed events leading to the acquired resistance to the targeted therapy in lung cancers and aid in the rational design of combined targeted therapies with durable antitumor effects.

Memberships

  • American Society of Pharmacology and Experimental Therapeutics (Member, 2012 - Present)
  • American Association for Cancer Research (Member, 2012 - Present)
  • American Association of Colleges of Pharmacy (Member, 2011 - Present)

Positions Held

  • Research Assistant Professor (Pharmacology and Systems Therapeutics, Mount Sinai School of Medicine 2009 - 2011)
  • Associate Scientist (School of Pharmacy, Temple University 2007 - 2009)
  • Post Doctoral Fellow (School of Pharmacy, Temple University 2004 - 2007)